Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Global Medical REIT (GMRE-PB) Shares Outstanding (Weighted Average) (2016 - 2025)

Global Medical REIT (GMRE-PB) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $13.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 1.46% year-over-year to $13.4 million, compared with a TTM value of $13.4 million through Dec 2025, up 1.46%, and an annual FY2025 reading of $13.4 million, up 1.46% over the prior year.
  • Shares Outstanding (Weighted Average) was $13.4 million for Q4 2025 at Global Medical REIT, roughly flat from $13.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $66.9 million in Q2 2025 and bottomed at $13.1 million in Q4 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $51.2 million, with a median of $65.4 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 34.78% in 2021, then plummeted 79.97% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $60.6 million in 2021, then rose by 7.95% to $65.5 million in 2022, then tumbled by 79.97% to $13.1 million in 2023, then grew by 0.59% to $13.2 million in 2024, then grew by 1.46% to $13.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for GMRE-PB at $13.4 million in Q4 2025, $13.4 million in Q3 2025, and $66.9 million in Q2 2025.